Axsome Therapeutics (AXSM) Change in Account Payables (2015 - 2026)

Axsome Therapeutics has reported Change in Account Payables for 12 years, with the latest figure at $41.2 million in Q1 2026.

• Quarterly Change in Account Payables rose 201.31% year-over-year to $41.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.0 million (down 33.97% YoY) and the FY2025 annual result came in at -$6.5 million, down 120.63% from the prior year.
• Change in Account Payables grew to $41.2 million in Q1 2026 per AXSM's latest filing, from $11.3 million in the prior quarter.
• Over five years, Change in Account Payables peaked at $41.2 million in Q1 2026 and troughed at -$37.4 million in Q3 2025.
• A 5-year average of $5.5 million and a median of $7.2 million in 2023 frame the typical range for Change in Account Payables.
• The sharpest annual moves came in 2022 and 2025: Change in Account Payables jumped 11172.43% in 2022, then plunged 1383.93% in 2025.
• Over 5 years, Change in Account Payables stood at $25.8 million in 2022, then plunged by 55.04% to $11.6 million in 2023, then plunged by 33.13% to $7.7 million in 2024, then surged by 46.05% to $11.3 million in 2025, then soared by 263.97% to $41.2 million in 2026.
• According to Business Quant data, Change in Account Payables over the past three periods registered $41.2 million, $11.3 million, and -$37.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.